Comment on ‘The dangers of non-randomized, observational studies. Experience from the COVID-19 epidemic’. Aspirin therapy in COVID-19: too soon to dismiss its benefits?-Reference-Cited by-同舟云学术

Comment on ‘The dangers of non-randomized, observational studies. Experience from the COVID-19 epidemic’. Aspirin therapy in COVID-19: too soon to dismiss its benefits?

Published:2023-03-01 Issue:4 Volume:78 Page:1134-1135
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Kow Chia Siang¹,Ramachandram Dinesh Sangarran²,Hasan Syed Shahzad³⁴

Affiliation:

1. School of Pharmacy, International Medical University , Kuala Lumpur , Malaysia

2. School of Pharmacy, Monash University Malaysia , Bandar Sunway, Selangor , Malaysia

3. School of Applied Sciences, University of Huddersfield , Huddersfield , UK

4. School of Biomedical Sciences & Pharmacy, University of Newcastle , Callaghan , Australia

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

https://academic.oup.com/jac/article-pdf/78/4/1134/49727906/dkad040.pdf

Reference8 articles.

1. The dangers of non-randomized, observational studies: experience from the COVID 19, epidemic;Hill;J Antimicrob Chemother,2022

2. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal;Khuroo;Int J Antimicrob Agents,2020

3. Author correction: mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials;Axfors;Nat Commun,2021

4. Is it worth the wait? Should chloroquine or hydroxychloroquine be allowed for immediate use in COVID-19?;Hasan,2020

5. Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19;Chow;JAMA Netw Open,2022